MoonLake Immunotherapeuti Stock Forward View - Simple Regression
| MLTX Stock | USD 16.73 -0.40 -2.34% |
Momentum
Impartial
Oversold | Overbought |
This view connects MoonLake Immunotherapeutics headline attention with price response and peer context.
The Simple Regression forecasted value of MoonLake Immunotherapeutics on the next trading day is expected to be 18.55 with a mean absolute deviation of 1.01 and the sum of the absolute errors of 61.31.MoonLake Immunotherapeuti after-hype prediction price | $ 16.73 |
This view helps relate attention signals to forecasting and technical indicators plus earnings context.
MoonLake | Build portfolio with MoonLake Stock |
MoonLake Immunotherapeuti Additional Predictive Modules
Predictive models for MoonLake Immunotherapeuti combine technical indicators with statistical methods to estimate probable price trajectories. Time-series models tend to perform better when fed clean, stationary data with consistent periodicity.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Simple Regression Price Forecast For the 17th of March 2026
Given 90 days horizon, the Simple Regression forecasted value of MoonLake Immunotherapeutics on the next trading day is expected to be 18.55 with a mean absolute deviation of 1.01 , mean absolute percentage error of 1.87 , and the sum of the absolute errors of 61.31 .Please note that although there have been many attempts to predict MoonLake Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that MoonLake Immunotherapeuti's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest MoonLake Immunotherapeuti | MoonLake Immunotherapeuti Price Prediction | Research Analysis |
Forecasted Value
The next-day forecast for MoonLake Immunotherapeutics focuses on identifying predictive downside and upside bands that can frame a realistic trading range. The projected forecast band currently runs from roughly 12.43 on the downside to about 24.66 on the upside.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of MoonLake Immunotherapeuti stock data series using in forecasting. Note that when a statistical model is used to represent MoonLake Immunotherapeuti stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 118.7351 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 1.0051 |
| MAPE | Mean absolute percentage error | 0.0664 |
| SAE | Sum of the absolute errors | 61.3111 |
The degree to which MoonLake Immunotherapeuti's exhibits mean reversion depends on how efficiently the market prices new information. In highly covered equities, the mean reversion window tends to be shorter.
After-Hype Price Density Analysis
The after-hype price distribution for MoonLake Immunotherapeuti helps investors understand how much of MoonLake Immunotherapeuti's predicted return comes from the central scenario versus tail outcomes. Strategies that rely on tail events for MoonLake Immunotherapeuti are inherently more speculative.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
Historical news patterns for MoonLake Immunotherapeuti reveal how the market has historically digested different types of information about MoonLake Immunotherapeuti's business and market environment. MoonLake Immunotherapeuti's after-hype downside and upside margins for the prediction period are 10.62 and 22.84, respectively. The model extrapolates these patterns to estimate likely price boundaries following the next significant.
Current Value
Macroaxis estimates the after-hype price of MoonLake Immunotherapeutics across a 3 months horizon to evaluate where the instrument could settle once headline distortion subsides. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as MoonLake Immunotherapeuti is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MoonLake Immunotherapeuti backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with MoonLake Immunotherapeuti, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.31 | 6.11 | 0.10 | 0.03 | 3 Events | 5 Events | In 3 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
16.73 | 16.73 | 0.00 |
|
Hype Timeline
MoonLake Immunotherapeuti is now traded for 16.73. The company has historical hype elasticity of -0.1, and average elasticity to hype of competition of -0.03. MoonLake is anticipated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is anticipated to be very small, whereas the daily expected return is now at 0.31%. %. The volatility of related hype on MoonLake Immunotherapeuti is about 5455.36%, with the expected price after the next announcement by competition of 16.70. About 81.0% of the company shares are owned by institutional investors. The book value of MoonLake Immunotherapeuti was now reported as 4.27. The company recorded a loss per share of 3.53. MoonLake Immunotherapeuti had not issued any dividends in recent years. Given the investment horizon of 90 days the next anticipated press release will be in 3 days. Cross-verify projections for MoonLake Immunotherapeuti using Historical Fundamental Analysis of MoonLake Immunotherapeuti. The view supplies historical context for the projection discussion.Related Hype Analysis
Peer hype analysis helps investors build a more complete picture of MoonLake Immunotherapeuti's competitive environment by quantifying the market's sensitivity to news across all major players in MoonLake Immunotherapeuti's sector.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| RGNX | Regenxbio | -0.31 | 3 per month | 0.00 | -0.10 | 6.52 | -7.96 | 25.89 | |
| MBX | MBX Biosciences Common | 0.00 | 0 per month | 4.48 | 0.05 | 13.41 | -7.47 | 29.11 | |
| ABSI | Absci Corp | 0.00 | 0 per month | 0.00 | -0.09 | 5.37 | -8.21 | 23.01 | |
| VSTM | Verastem | -0.31 | 9 per month | 0.00 | -0.14 | 5.85 | -7.51 | 19.78 | |
| MGTX | MeiraGTx Holdings PLC | 0.04 | 7 per month | 0.00 | -0.04 | 5.08 | -5.67 | 16.37 | |
| ERAS | Erasca Inc | 0.04 | 21 per month | 2.52 | 0.33 | 15.04 | -5.48 | 50.26 | |
| VTYX | Ventyx Biosciences | -0.31 | 6 per month | 1.48 | 0.17 | 12.92 | -6.33 | 37.04 | |
| AVBP | ArriVent BioPharma Common | 0.04 | 13 per month | 3.04 | 0.04 | 6.71 | -4.93 | 18.15 | |
| OLMA | Olema Pharmaceuticals | -0.31 | 22 per month | 0.00 | -0.20 | 6.25 | -7.02 | 35.57 | |
| CTMX | CytomX Therapeutics | 0.00 | 0 per month | 3.24 | 0.13 | 8.21 | -5.92 | 36.75 |
Other Forecasting Options for MoonLake Immunotherapeuti
The price trajectory of MoonLake is the primary concern for any investor assessing it as an opportunity. MoonLake Stock price charts are filled with noise that can easily mislead uninformed investment decisions.MoonLake Immunotherapeuti Related Equities
The following equities are related to MoonLake Immunotherapeuti within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing MoonLake Immunotherapeuti against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
MoonLake Immunotherapeuti Market Strength Events
Understanding the market strength of MoonLake Immunotherapeuti stock enables investors to assess the security's momentum and responsiveness to broader market forces. These indicators are essential tools for timing trades in MoonLake Immunotherapeutics with greater precision.
MoonLake Immunotherapeuti Risk Indicators
Reviewing MoonLake Immunotherapeuti's basic risk indicators is essential for investors who want to forecast its price and manage their investment risk effectively. This analysis helps identify the amount of risk involved in holding MoonLake Immunotherapeuti's and informs decisions about hedging and position.
| Mean Deviation | 3.25 | |||
| Semi Deviation | 3.59 | |||
| Standard Deviation | 6.11 | |||
| Variance | 37.37 | |||
| Downside Variance | 15.51 | |||
| Semi Variance | 12.91 | |||
| Expected Short fall | -3.70 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for MoonLake Immunotherapeuti
A coverage review of MoonLake Immunotherapeutics helps investors see when the security is attracting above-average attention from contributors and market observers. The practical risk is that faster visibility can increase both interest and skepticism at the same time.
Contributor Headline
Latest Perspective From Macroaxis
MoonLake Immunotherapeuti Short Properties
A short-interest review of MoonLake Immunotherapeutics helps investors understand whether skepticism in the market is becoming more influential. A disciplined short-interest review can make timing decisions more informed under rising skepticism.
| Common Stock Shares Outstanding | 64.5 M | |
| Cash And Short Term Investments | 394 M |
More Resources for MoonLake Stock Analysis
A comprehensive view of MoonLake Immunotherapeuti starts with financial statements and ratio context. Ratio analysis helps investors evaluate MoonLake Immunotherapeutics Stock operating efficiency and financial trajectory. Highlighted below are reports that provide context for MoonLake Immunotherapeutics Stock:Cross-verify projections for MoonLake Immunotherapeuti using Historical Fundamental Analysis of MoonLake Immunotherapeuti. The view supplies historical context for the projection discussion.MoonLake Immunotherapeuti currently shows ROE of -60.78%, market cap of 1.23 Billion. MoonLake Immunotherapeuti analysis should be paired with portfolio risk and diversification tools before adjusting allocations. Within the Healthcare space, MoonLake Immunotherapeuti peer comparison and risk tools below help frame relative strengths and weaknesses. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Understanding MoonLake Immunotherapeuti includes distinguishing between market value and book value, where book value reflects MoonLake's accounting equity. MoonLake Immunotherapeuti's market capitalization is 1.23 B. At P/B 4.04, MoonLake Immunotherapeuti trades at a significant premium to book value. Enterprise value stands at 910.44 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for MoonLake Immunotherapeuti are related but not identical, and they can diverge across cycles. For MoonLake Immunotherapeuti, key inputs include a P/B ratio of 4.04, and ROE of -60.78%. The quoted MoonLake Immunotherapeuti price is the exchange level where supply meets demand.